Techniques to target the adaptive immune system have included injection of autologous dendritic cells expanded ex vivo via transduction with human gp100, a melanoma antigen, as an adjuvant to radiation therapy [15], as well as allogeneic whole-cell tumor vaccines expressing various melanoma antigens [16]. Here, PMEL is linked to melanoma.